Navigation Links
Results of the ADVISE trial reported at TCT 2011
Date:11/11/2011

SAN FRANCISCO, CA NOVEMBER 11, 2011 Researchers conducting the ADVISE clinical trial have concluded that a new measure of stenosis severity, instantaneous wave-free ratio (iFR), yielded similar results to traditional fractional flow reserve (FFR) without the use of adenosine to induce maximum hyperemia. Trial results were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

FFR, while the leading invasive measure of stenosis severity, is only used in 6% or fewer of percutaneous coronary intervention (PCI) cases in the United States. One of the reasons for the low usage rate is the required use of the drug adenosine, which minimizes and stabilizes coronary resistance during the test, but is uncomfortable for patients, as well as being time-consuming and expensive.

In ADVISE (ADenosine Vasodilation Independent Stenosis Evaluation), 157 stenoses (131 patients) were recruited to this pilot, nonrandomized, international, multi-center study. In their investigations, researchers developed a new pressure-based index that does not require adenosine.

Wave intensity analysis identified a period during the normal heart rhythm cycle where intracoronary resistance at rest is similar in variability and magnitude (CV: 0.080.06 and 284147mmHg.s/m) to those during FFR (CV: 0.080.06 and 302315mmHg.s/m, p=NS for both).

The resting ratio of the distal-to-proximal pressure during this period, iFR, correlated closely with FFR (r=0.9, p<0.001) with excellent diagnostic efficiency (receiver operating characteristic area under curve of 93%, at FFR<0.8), specificity, sensitivity, and negative and positive predictive values of 91%, 85%, 85% and 91%, respectively.

"The results of the ADVISE trial indicate that intra-coronary resistance is naturally constant and minimized during the wave-free period. The instantaneous wave-Free Ratio (iFR) calculated over this period produces a drug-free index of stenosis severity that is comparable to FFR," said principal investigator Justin Davies, MBBS, MRCP, PhD. Dr Davies is a clinical academic and interventional cardiologist at the National Heart and Lung Institute at Imperial College London.

"The clinical implications of the trial are that significant barriers to a physiological assessment of stenoses have been removed, and the new technique can potentially improve work-flow in the cath lab, leading to a better patient experience and increased adoption," said Dr. Davies.


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2009 Financial Results
2. SXC Health Solutions to Host Fiscal 2009 Fourth Quarter and Year End Results Conference Call
3. Team Health Holdings, Inc., Announces Fourth Quarter and Fiscal 2009 Financial Results
4. First blinded study of venous insufficiency prevalence in MS shows promising results
5. NEJM Publishes Trial Results Demonstrating Bard FLAIR Endovascular Stent Graft Is Superior To Balloon Angioplasty For Failing Dialysis Grafts
6. BioMed Realty Trust Reports Fourth Quarter and Full-Year 2009 Financial Results
7. Kaiser Foundation Health Plan and Hospitals Report Fourth Quarter and Fiscal Year 2009 Financial Results
8. United American Healthcare Corporation Announces Fiscal 2010 Second Quarter Results
9. Fitness Trend Towards Online Personal Training Gets Real-World Weight Loss Results on FitOrbit.com
10. Protein Sciences Corporation Announces Profitable and Cash Flow Positive Results for 2009 and Management Realignment
11. WebMD Announces Fourth Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... is actively feeding the Frederick area economy by obtaining investment capital for emerging ... the past 2½ years that have already resulted in more than a million ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, MTI-GlobalStem, a provider of ... other difficult to transfect cells, announces its launch of the PluriQ™ G9™ Gene ... System is a complete system for culturing and transfecting human pluripotent stem ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of ... their offering. The current ... environment for MedImmune to enter. The US ageing population creates ... drive considerable growth for effective anti-influenza medications. The introduction of ... but development is still in its infancy. ...
(Date:6/23/2016)... MOUNTAIN VIEW, Calif. , June 23, 2016 ... 9:00 a.m. CST on Thursday, July 7, 2016 , , ... kayla.belcher@frost.com ) , , , , EXPERT PANELISTS:  ... Sciences, Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, ... The global pharmaceutical industry is witnessing ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia ... the company,s second affiliate in Latin America . ... ... Farma Colombia ... ...
Breaking Medicine Technology: